A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1860-1866

  Maemondo, M ^a,b   Masuda, N ^c   Sekine, I ^d   Kubota, K ^e   Segawa, Y ^f   Shibuya, M ^g   Imamura, F ^h   Katakami, N ⁱ   Hida, T ^j   Takeo, S ^k   Isobe, Hiroshi ^l   Kikuchi, Yoshihiro ^m   Ando, Masahiro ⁿ   Yokoyama, Akira ^o   Miyao, Hiromi ^p   Fujii, Hirofumi ^q   Sakai, Hiroshi ^r   Yoshimori, Kouzou ^s   Genma, Akihiko ^t   Takeda, Yuichiro ^u   Masahiro, Tsuboi ^v   Arai, Hiroharu ^w   Ogura, Takashi ^x   Koizumi, Wasaburo ^c   Eguchi, Kenji ^y   Kitagawa, Chiyoe ^z   Sawa, Toshiyuki ^aa   Atagi, Shinji ^ab   Ogawara, Mitsumasa ^ab   Nishimura, Takashi ^ac   Negoro, Shunichi ^ad   Kiura, Katsuyuki ^ae   Shigeoka, Yasushi ^af   Ichinose, Yukito ^ag   Senba, Hiroshi ^ah   more..

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b Miyagi Cancer Center   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^l HOKKAIDO CANCER CENTER   (Japan)

^m SENDAI CITY MEDICAL CENTER   (Japan)

ⁿ Tsuboi Cancer Center Hospital   (Japan)

^o Niigata Cancer Center   (Japan)

^p NISHI NIIGATA CHUO NATIONAL HOSPITAL   (Japan)

^q TOCHIGI CANCER CENTER   (Japan)

^r SAITAMA CANCER CENTER   (Japan)

^s Japan Anti Tuberculosis Association   (Japan)

^t NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^u NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^v TOKYO MEDICAL UNIVERSITY   (Japan)

^w NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^x Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^y TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^z NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^aa Gifu Municipal Hospital   (Japan)

^ab NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^ac KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^ad HYOGO CANCER CENTER   (Japan)

^ae OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^af TOTTORI UNIVERSITY   (Japan)

^ag NATIONAL KYUSHU CANCER CENTER   (Japan)

^ah KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

more..

Author keywords

5 HT3 receptor antagonist; CINV; Emesis; Palonosetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; PACLITAXEL; PALONOSETRON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLD SWEAT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HICCUP; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 71049156164     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp195     Document Type: Article

References (23)

1. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-4478.
2. Cohen L, de Moor CA, Eisenberg P et al. Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007; 15: 497-503.
3. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997; 33: 66-74.
4. McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw 2007; 5: 35-43.
5. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004; 64: 1125-1132; discussion 1133-1134.
6. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44: 520-531.
7. Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004; 25: 329-337.
8. Eisenberg P, MacKintosh FR, Ritch P et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study. Ann Oncol 2004; 15: 330-337.
9. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
10. Hesketh PJ, Harvey WH, Harker WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
11. Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996; 7: 945-952.
12. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15: 2966-2973.
13. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-3422.
14. Bookman MA, Kloth DD, Kover PE et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8: 611-614.
15. Markman M, Kennedy A, Webster K et al. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125: 427-429.
16. Ohmatsu H, Eguchi K, Shinkai T et al. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res 1994; 85: 1151-1158.
17. Sekine I, Nishiwaki Y, Kakinuma R et al. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: The role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Jpn J Clin Oncol 1996; 26: 164-168.
18. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
19. Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007; 18 (Suppl 2): Ii83-ii85.
20. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
21. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
22. Ettinger DS, Bierman PJ, Bradbury B et al. Antiemesis. J Natl Compr Canc Netw 2007; 5: 12-33.
23. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.